AU2020351698A1 - IL-15 fusion peptides used to treat cancer - Google Patents

IL-15 fusion peptides used to treat cancer Download PDF

Info

Publication number
AU2020351698A1
AU2020351698A1 AU2020351698A AU2020351698A AU2020351698A1 AU 2020351698 A1 AU2020351698 A1 AU 2020351698A1 AU 2020351698 A AU2020351698 A AU 2020351698A AU 2020351698 A AU2020351698 A AU 2020351698A AU 2020351698 A1 AU2020351698 A1 AU 2020351698A1
Authority
AU
Australia
Prior art keywords
fusion polypeptide
seq
sequence
polypeptide according
sequence identity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020351698A
Other languages
English (en)
Inventor
Prokar DASGUPTA
Christine Galustian
Efthymia PAPAEVANGELOU
Richard Smith
Dorota SMOLAREK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
King's College London
Prostate Cancer Research
Original Assignee
King's College London
Prostate Cancer Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by King's College London, Prostate Cancer Research filed Critical King's College London
Publication of AU2020351698A1 publication Critical patent/AU2020351698A1/en
Assigned to KING'S COLLEGE LONDON, Prostate Cancer Research reassignment KING'S COLLEGE LONDON Amend patent request/document other than specification (104) Assignors: KING'S COLLEGE LONDON, Prostate cancer research centre
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU2020351698A 2019-09-25 2020-09-25 IL-15 fusion peptides used to treat cancer Abandoned AU2020351698A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201913804A GB201913804D0 (en) 2019-09-25 2019-09-25 Fusion polypeptides
GB1913804.9 2019-09-25
PCT/GB2020/052328 WO2021058973A1 (en) 2019-09-25 2020-09-25 Il-15 fusion peptides used to treat cancer

Publications (1)

Publication Number Publication Date
AU2020351698A1 true AU2020351698A1 (en) 2022-03-31

Family

ID=68425465

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020351698A Abandoned AU2020351698A1 (en) 2019-09-25 2020-09-25 IL-15 fusion peptides used to treat cancer

Country Status (9)

Country Link
US (1) US20220372097A1 (cg-RX-API-DMAC7.html)
EP (1) EP4034552A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023502843A (cg-RX-API-DMAC7.html)
CN (1) CN114651014A (cg-RX-API-DMAC7.html)
AU (1) AU2020351698A1 (cg-RX-API-DMAC7.html)
CA (1) CA3155100A1 (cg-RX-API-DMAC7.html)
GB (1) GB201913804D0 (cg-RX-API-DMAC7.html)
IL (1) IL291560A (cg-RX-API-DMAC7.html)
WO (1) WO2021058973A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
GB202304385D0 (en) 2023-03-24 2023-05-10 Prostate Cancer Res Combinatorial IL-15 therapy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
GB9614871D0 (en) 1996-07-15 1996-09-04 Smithkline Beecham Plc Compounds
US20070160578A1 (en) * 2005-12-14 2007-07-12 The Gov. Of The Usa As Represented By The Secretary Of The Dep. Of Health And Human Services Expansion of natural killer and CD8 T-cells with IL-15R/ligand activator complexes
GB0915519D0 (en) 2009-09-04 2009-10-07 King S College London Ntithrombotic compounds
AU2011317211B2 (en) * 2010-10-22 2015-04-16 Dana-Farber Cancer Institute, Inc. Discovery of regulatory T cells programmed to suppress an immune response
WO2018161026A1 (en) * 2017-03-03 2018-09-07 Obsidian Therapeutics, Inc. Il15 compositions and methods for immunotherapy
AU2018291497A1 (en) * 2017-06-30 2020-01-16 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains
JP7386161B2 (ja) * 2017-12-19 2023-11-24 ブレイズ バイオサイエンス, インコーポレイテッド 腫瘍ホーミング及び細胞透過性ペプチド免疫抗がん剤複合体、ならびにそれらの使用方法
MX387358B (es) * 2018-02-28 2025-03-18 Pfizer Variantes de il-15 y usos de las mismas
CA3090407A1 (en) * 2018-03-01 2019-09-06 Glycotope Gmbh Fusion protein constructs comprising an anti-muc1 antibody and il-15

Also Published As

Publication number Publication date
GB201913804D0 (en) 2019-11-06
WO2021058973A1 (en) 2021-04-01
JP2023502843A (ja) 2023-01-26
US20220372097A1 (en) 2022-11-24
EP4034552A1 (en) 2022-08-03
IL291560A (en) 2022-05-01
CN114651014A (zh) 2022-06-21
CA3155100A1 (en) 2021-04-01

Similar Documents

Publication Publication Date Title
KR101731655B1 (ko) 암 억제 방법
Siebert et al. Tuftsin-properties and analogs
US20090304666A1 (en) Conjugate for the specific targeting of anticancer agents to tumor cells or tumor vasculature and production thereof
JP2018076333A (ja) コンドロイチン硫酸グリカンのターゲティング
EP3065829B1 (en) Compositions and methods for treating melanoma
US20220372097A1 (en) Il-15 fusion peptides used to treat cancer
CN107249641B (zh) 用于特异性诱导针对靶细胞的t细胞细胞毒性的免疫缀合物
MA31062B1 (fr) Agents tensioactifs reconstitues presentant des proprietes ameliorees.
CN115702159A (zh) Ngr偶联物及其用途
JP6218175B2 (ja) ヘルパーt細胞誘導性ポリペプチドの改変
AU2012318609B2 (en) Dimeric bacteriophage lysins
TW201902935A (zh) 蛋白質結合物
JP7701276B2 (ja) 併用療法
WO2024201004A1 (en) Combinatorial il-15 therapy
EP3828268A1 (en) Fragmented grs polypeptide and variant thereof, and use thereof
JP2022526978A (ja) ヒト血清の存在下でシュードモナス・エルギノーサに対する殺菌活性を有する溶解素及びその誘導体
JP2025511684A (ja) 新規ペプチドベースの免疫抗癌剤
US20250041337A1 (en) Fusion protein
RU2807688C9 (ru) Идентификация лизинов и их производных, обладающих антибактериальной активностью против pseudomonas aeruginosa
RU2807688C2 (ru) Идентификация лизинов и их производных, обладающих антибактериальной активностью против pseudomonas aeruginosa
Zhu et al. An uPA cleavable conjugate of a recombinant αvβ3 targeting toxin and its bioactivity
HK40078054A (en) Combination therapy
US20100331239A1 (en) Cd14 and peptides thereof for protection of cells against cell death
Rogers Novel Methods of Targeting Protein Cytotoxins to Metastatic Prostate Tumors: Teaching" Old Proteins" New Tricks
Oberoi et al. EGFR-Targeted Granzyme B Expressed in NK Cells Enhances Natural Cytotoxicity and

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: KING'S COLLEGE LONDON

Free format text: FORMER NAME(S): KING'S COLLEGE LONDON; PROSTATE CANCER RESEARCH CENTRE

Owner name: PROSTATE CANCER RESEARCH

Free format text: FORMER NAME(S): KING'S COLLEGE LONDON; PROSTATE CANCER RESEARCH CENTRE

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application